Lisa A Carey

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. pmc TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer
    Lisa A Carey
    Hematology Oncology, University of North Carolina Lineberger Comprehensive Cancer Center, 170 Manning Dr, Chapel Hill, NC 27599 7305, USA
    J Clin Oncol 30:2615-23. 2012
  2. pmc A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
    Nancy U Lin
    Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
    Breast Cancer Res Treat 133:1057-65. 2012
  3. pmc An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer
    Andrea H Bild
    Department of Pharmacology and Toxicology, University of Utah, 112 Skaggs Hall, Salt Lake City, UT 84112, USA
    Breast Cancer Res 11:R55. 2009
  4. doi request reprint Directed therapy of subtypes of triple-negative breast cancer
    Lisa A Carey
    University of North Carolina, Chapel Hill, North Carolina 27599 7305, USA
    Oncologist 16:71-8. 2011
  5. ncbi request reprint Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
    Lisa A Carey
    Division of Hematology Oncology, School of Public Health, Department of Epidemiology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599 7305, USA
    JAMA 295:2492-502. 2006
  6. doi request reprint Directed therapy of subtypes of triple-negative breast cancer
    Lisa A Carey
    University of North Carolina, Chapel Hill, North Carolina 27599 7305, USA
    Oncologist 15:49-56. 2010
  7. ncbi request reprint American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome
    Lisa A Carey
    Division of Hematology Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27599 7305, USA
    J Natl Cancer Inst 97:1137-42. 2005
  8. ncbi request reprint Central nervous system metastases in women after multimodality therapy for high risk breast cancer
    Lisa A Carey
    Division of Hematology Oncology, Department of Medicine, University of North Carolina, 3009 Old Clinic Building, Chapel Hill, NC, 27599 7305, USA
    Breast Cancer Res Treat 88:273-80. 2004
  9. ncbi request reprint Through a glass darkly: advances in understanding breast cancer biology, 2000-2010
    Lisa A Carey
    Department of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, USA
    Clin Breast Cancer 10:188-95. 2010
  10. ncbi request reprint The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes
    Lisa A Carey
    Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7305, USA
    Clin Cancer Res 13:2329-34. 2007

Detail Information

Publications73

  1. pmc TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer
    Lisa A Carey
    Hematology Oncology, University of North Carolina Lineberger Comprehensive Cancer Center, 170 Manning Dr, Chapel Hill, NC 27599 7305, USA
    J Clin Oncol 30:2615-23. 2012
    ..Epidermal growth factor receptor (EGFR) is a targetable receptor frequently overexpressed in basal-like breast cancer, which comprises most triple-negative breast cancers (TNBCs), the only subtype without established targeted therapy...
  2. pmc A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
    Nancy U Lin
    Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
    Breast Cancer Res Treat 133:1057-65. 2012
    ..4%) and rash (9.8%). Afatinib monotherapy was associated with promising clinical activity in extensively pretreated HER2-positive breast cancer patients who had progressed following trastuzumab treatment...
  3. pmc An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer
    Andrea H Bild
    Department of Pharmacology and Toxicology, University of Utah, 112 Skaggs Hall, Salt Lake City, UT 84112, USA
    Breast Cancer Res 11:R55. 2009
    ..Additional work has also used signatures of oncogenic pathway deregulation to dissect breast cancer heterogeneity as well as to suggest therapeutic opportunities linked to pathway activation...
  4. doi request reprint Directed therapy of subtypes of triple-negative breast cancer
    Lisa A Carey
    University of North Carolina, Chapel Hill, North Carolina 27599 7305, USA
    Oncologist 16:71-8. 2011
    ..This article addresses the nature of, and therapeutic strategies for, triple-negative breast cancer...
  5. ncbi request reprint Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
    Lisa A Carey
    Division of Hematology Oncology, School of Public Health, Department of Epidemiology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599 7305, USA
    JAMA 295:2492-502. 2006
    ..Gene expression analysis has identified several breast cancer subtypes, including basal-like, human epidermal growth factor receptor-2 positive/estrogen receptor negative (HER2+/ER-), luminal A, and luminal B...
  6. doi request reprint Directed therapy of subtypes of triple-negative breast cancer
    Lisa A Carey
    University of North Carolina, Chapel Hill, North Carolina 27599 7305, USA
    Oncologist 15:49-56. 2010
    ..This article addresses the nature of, and therapeutic strategies for, triple-negative breast cancer...
  7. ncbi request reprint American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome
    Lisa A Carey
    Division of Hematology Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27599 7305, USA
    J Natl Cancer Inst 97:1137-42. 2005
    ....
  8. ncbi request reprint Central nervous system metastases in women after multimodality therapy for high risk breast cancer
    Lisa A Carey
    Division of Hematology Oncology, Department of Medicine, University of North Carolina, 3009 Old Clinic Building, Chapel Hill, NC, 27599 7305, USA
    Breast Cancer Res Treat 88:273-80. 2004
    ..This increase may reflect altered failure patterns from adjuvant therapy, more effective systemic therapy with improved control in non-CNS sites, or a resistant breast cancer subtype...
  9. ncbi request reprint Through a glass darkly: advances in understanding breast cancer biology, 2000-2010
    Lisa A Carey
    Department of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, USA
    Clin Breast Cancer 10:188-95. 2010
    ..These include the need for more tissue-based studies to allow us to understand the mechanisms of sensitivity and resistance within and across subtypes, and the need to revisit risk and prevention by subtype...
  10. ncbi request reprint The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes
    Lisa A Carey
    Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7305, USA
    Clin Cancer Res 13:2329-34. 2007
    ..Gene expression analysis identifies several breast cancer subtypes. We examined the relationship of neoadjuvant chemotherapy response to outcome among these breast cancer subtypes...
  11. ncbi request reprint Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide
    Hanna Kelly
    Department of Medicine, University of North Carolina at Chapel Hill, NC 27599 7305, USA
    Clin Breast Cancer 7:237-43. 2006
    ..This phase II study was undertaken to determine the neoadjuvant clinical and pathologic response rate and the acute and chronic cardiac toxicity of trastuzumab given with weekly paclitaxel after AC (doxorubicin/cyclophosphamide)...
  12. ncbi request reprint Axillary lymph node count is lower after neoadjuvant chemotherapy
    Heather Neuman
    Department of Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    Am J Surg 191:827-9. 2006
    ..We postulated that despite aggressive ALND, a lower lymph node count is more frequent after neoadjuvant chemotherapy...
  13. ncbi request reprint Size of residual lymph node metastasis after neoadjuvant chemotherapy in locally advanced breast cancer patients is prognostic
    Nancy Klauber-Demore
    Department of Surgery, University of North Carolina at Chapel Hill, 27599, USA
    Ann Surg Oncol 13:685-91. 2006
    ..We examined the residual lymph node metastasis size in patients after treatment with neoadjuvant chemotherapy to determine the relevance of metastasis size on outcome...
  14. doi request reprint Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer
    William J Irvin
    The Lineberger Comprehensive Cancer Center, and Division of Hematology Oncology, School of Medicine, University of North Carolina at Chapel Hill, 170 Manning Drive, Chapel Hill, NC 27599, USA
    Clin Breast Cancer 10:465-70. 2010
    ....
  15. pmc A compact VEGF signature associated with distant metastases and poor outcomes
    Zhiyuan Hu
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    BMC Med 7:9. 2009
    ..Tumor metastases pose the greatest threat to a patient's survival, and thus, understanding the biology of disseminated cancer cells is critical for developing effective therapies...
  16. doi request reprint Knowledge of genomic testing among early-stage breast cancer patients
    Alice R Richman
    Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC 27599, USA
    Psychooncology 20:28-35. 2011
    ..Genomic recurrence risk test results now inform clinical decisions about adjuvant treatment for women with early-stage breast cancer. We sought to understand patients' knowledge of these tests and correlates of their knowledge...
  17. ncbi request reprint Women's interest in gene expression analysis for breast cancer recurrence risk
    Suzanne C O'Neill
    University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA
    J Clin Oncol 25:4628-34. 2007
    ..We assessed interest in genomic RFR testing and patient preferences for incorporating results into treatment decision making...
  18. doi request reprint The interaction of post-traumatic growth and post-traumatic stress symptoms in predicting depressive symptoms and quality of life
    E Forrest Morrill
    The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Psychooncology 17:948-53. 2008
    ....
  19. pmc Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study
    Katie M O'Brien
    Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Clin Cancer Res 16:6100-10. 2010
    ....
  20. pmc Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases
    Barbara Adamo
    Department of Medicine, Division of Hematology Oncology, CB 7305, University of North Carolina, Chapel Hill, NC 27599, USA
    Breast Cancer Res 13:R125. 2011
    ..Secondary analyses included PI3K pathway activation status and associations with time to distant recurrence (TTDR) and time to BCBMs. Similar analyses were also conducted among the subset of patients with triple-negative BCBMs...
  21. pmc EGFR associated expression profiles vary with breast tumor subtype
    Katherine A Hoadley
    Curriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    BMC Genomics 8:258. 2007
    ..An EGFR-associated gene expression signature was identified in the basal-like SUM102 cell line and was used to classify a diverse set of sporadic breast tumors...
  22. doi request reprint Impact of breast cancer molecular subtypes on locoregional recurrence in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer
    Michael O Meyers
    Division of Surgical Oncology, Department of Surgery, University of North Carolina School of Medicine at Chapel Hill, Chapel Hill, NC, USA
    Ann Surg Oncol 18:2851-7. 2011
    ..The impact of subtypes on locoregional recurrence (LRR) after neoadjuvant chemotherapy for locally advanced breast cancer is unknown...
  23. pmc Blood vessel morphologic changes depicted with MR angiography during treatment of brain metastases: a feasibility study
    Elizabeth Bullitt
    Computer Assisted Surgery and Imaging Laboratory, University of North Carolina, 247 Wing E, CB 7062, Chapel Hill, NC 27599, USA
    Radiology 245:824-30. 2007
    ....
  24. ncbi request reprint Lymphatic mapping and sentinel lymphadenectomy prior to neoadjuvant chemotherapy in patients with large breast cancers
    David W Ollila
    Division of Surgical Oncology, Department of Surgery, University of North Carolina, Chapel Hill, NC 27599, USA
    Am J Surg 190:371-5. 2005
    ..LM/SL in patients with large breast cancers is controversial. We examined the accuracy of LM/SL prior to neoadjuvant chemotherapy in patients with large (>3.5 cm) breast cancers...
  25. pmc The molecular portraits of breast tumors are conserved across microarray platforms
    Zhiyuan Hu
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    BMC Genomics 7:96. 2006
    ..To overcome this problem we used publicly available breast cancer gene expression data sets and a novel approach to data fusion, in order to validate a new breast tumor intrinsic list...
  26. pmc Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures
    Cheng Fan
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, USA
    BMC Med Genomics 4:3. 2011
    ..We evaluated whether combining the prognostic powers of standard breast cancer clinical variables with a large set of gene expression signatures could improve on our ability to predict patient outcomes...
  27. ncbi request reprint Young women with locally advanced breast cancer who achieve breast conservation after neoadjuvant chemotherapy have a low local recurrence rate
    Raeshell S Sweeting
    Division of Surgical Oncology, University of North Carolina School of Medicine at Chapel Hill, Chapel Hill, North Carolina, USA
    Am Surg 77:850-5. 2011
    ..This suggests that neoadjuvant chemotherapy may identify young women for whom BCT may have an acceptable risk of LRR...
  28. doi request reprint When genomic and standard test results diverge: implications for breast cancer patients' preference for chemotherapy
    Noel T Brewer
    Department of Health Behavior and Health Education, University of North Carolina, Chapel Hill, 27516, USA
    Breast Cancer Res Treat 117:25-9. 2009
    ..We examined how women incorporate potentially differing genomic and standard assessments of breast cancer recurrence risk into chemotherapy decisions...
  29. pmc Understanding how breast cancer patients use risk information from genomic tests
    Jessica T DeFrank
    Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina, 325 Rosenau Hall, CB 7440, Chapel Hill, NC, 27599 7440, USA
    J Behav Med 36:567-73. 2013
    ..When test results conflicted, women gave more weight to genomic over standard test results. Hypothetical genomic test results had the intended effect of influencing women's perceptions of recurrence risk and interest in chemotherapy. ..
  30. pmc Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer
    Hanna K Sanoff
    Affiliations of authors Lineberger Comprehensive Cancer Center HKS, AMD, JK, CT, JS, JGI, LAC, AD, B BG, SA, NES, HBM, Department of Medicine HKS, Taj, GW, LAC, NES, HBM, Department of Genetics JK, CT, NES, and Department of Biostatistics JGI, University of North Carolina, Chapel Hill, NC Department of Medicine, University of Virginia, Charlottesville, VA PD Department of Medical Oncology and Therapeutics Research, City of Hope Cancer Center, Duarte, CA AH Leibniz Institute for Age Research, Fritz Lipmann Institute, Jena, Germany KK, KLR
    J Natl Cancer Inst 106:dju057. 2014
    ..To understand whether cytotoxic agents promote molecular aging, we measured expression of p16 (INK4a) and other senescence markers in breast cancer patients treated with adjuvant chemotherapy...
  31. pmc Improving communication of breast cancer recurrence risk
    Noel T Brewer
    Department of Health Behavior and Health Education, UNC Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC 27599 7440, USA
    Breast Cancer Res Treat 133:553-61. 2012
    ..A less complex report, potentially including the risk continuum format, would be more effective in communicating test results to patients...
  32. pmc Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study
    Matthew J Ellis
    Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, MO 63110, USA
    JAMA 302:774-80. 2009
    ..Estrogen deprivation therapy with aromatase inhibitors has been hypothesized to paradoxically sensitize hormone-receptor-positive breast cancer tumor cells to low-dose estradiol therapy...
  33. pmc Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial
    John A Olson
    Department of Surgery, Duke Comprehensive Cancer Center, Durham, NC, USA
    J Am Coll Surg 208:906-14; discussion 915-6. 2009
    ..A multicenter phase II clinical trial was conducted to investigate the value of this approach for US surgical practice...
  34. doi request reprint A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors
    E Claire Dees
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    Cancer Chemother Pharmacol 63:99-107. 2008
    ..We conducted a phase I trial of bortezomib and pegylated liposomal doxorubicin (PLD) in patients with refractory solid tumors...
  35. doi request reprint Women's experiences with genomic testing for breast cancer recurrence risk
    Janice P Tzeng
    Department of Health Behavior and Health Education, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Cancer 116:1992-2000. 2010
    ..This study examined how women receive and incorporate results of Oncotype DX, a genomic test that offers recurrence risk estimates, into decisions about adjuvant treatment for early stage breast cancer...
  36. pmc Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival
    William G Cance
    Department of Surgery, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 27599, USA
    Ann Surg 236:295-302; discussion 302-3. 2002
    ..The authors determined the rate of breast preservation, the disease-free and overall survival, and the factors associated with locoregional and distant recurrent disease...
  37. doi request reprint The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases
    Carey K Anders
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7305, USA
    Cancer 117:1602-11. 2011
    ..In a single-institution cohort study, the authors attempted to determine whether the inferior outcome noted with TNBC brain metastases is more reflective of a higher risk population or the subtype itself...
  38. pmc CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel
    Daniel L Hertz
    UNC Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill, 120 Mason Farm Road, CB 7361, Chapel Hill, NC 27599, USA
    Breast Cancer Res Treat 134:401-10. 2012
    ..Patients carrying CYP2C8*3 are more likely to achieve clinical complete response from neoadjuvant paclitaxel treatment, but may also be at increased risk of experiencing severe peripheral neurotoxicity...
  39. pmc Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer
    Carey K Anders
    University of North Carolina, Chapel Hill, 27517, USA
    Clin Cancer Res 16:4702-10. 2010
    ....
  40. pmc Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study
    William J Irvin
    University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    J Clin Oncol 29:3232-9. 2011
    ....
  41. ncbi request reprint High-resolution axillary ultrasound is a poor prognostic test for determining pathologic lymph node status in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer
    Nancy Klauber-Demore
    Department of Surgery, University of North Carolina at Chapel Hill, 3010 Old Clinic Bldg, CB No 7213, Chapel Hill, NC 27599, USA
    Am J Surg 188:386-9. 2004
    ..The purpose of this study was to evaluate the efficacy of high-resolution axillary ultrasound in detecting axillary lymph node metastases after neoadjuvant chemotherapy in patients with locally advanced breast cancer...
  42. ncbi request reprint What is triple-negative breast cancer?
    William J Irvin
    Department of Medicine, Division of Hematology Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599 7305, USA
    Eur J Cancer 44:2799-805. 2008
    ..This review discusses the definitions and characteristics of as well as current and evolving therapies for triple-negative and basal-like breast cancer...
  43. doi request reprint Molecular subtypes in breast cancer evaluation and management: divide and conquer
    Jeffrey Peppercorn
    University of North Carolina, Chapel Hill, North Carolina, USA
    Cancer Invest 26:1-10. 2008
  44. ncbi request reprint Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers
    Daniel S Oh
    Department of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    J Clin Oncol 24:1656-64. 2006
    ..Therefore, we developed a gene expression-based outcome predictor for ER+ and/or PR+ (ie, luminal) breast cancer patients using biologic differences among these tumors...
  45. ncbi request reprint Treatment of single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local control
    Matthew G Ewend
    University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Clin Cancer Res 13:3637-41. 2007
    ..To define the safety and efficacy of carmustine polymer wafers when added to a regimen of surgery and external beam radiotherapy for treatment of a single brain metastasis...
  46. ncbi request reprint CYP2D6 and tamoxifen: DNA matters in breast cancer
    Janelle M Hoskins
    UNC Institute for Pharmacogenomics and Individualized Therapy, Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina, Chapel Hill, 27599, North Carolina, USA
    Nat Rev Cancer 9:576-86. 2009
    ..Here we review the existing data that relate CYP2D6 genotypes to response to tamoxifen and discuss whether the analysis of the CYP2D6 genotype might be an early example of a pharmacogenetic tool for optimizing breast cancer therapy...
  47. ncbi request reprint Retention and use of breast cancer recurrence risk information from genomic tests: the role of health literacy
    Sarah E Lillie
    University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Cancer Epidemiol Biomarkers Prev 16:249-55. 2007
    ..Because these genomic tests are so new, little is known about how well patients understand the tests and their results...
  48. pmc Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer
    Carey K Anders
    Department of Medicine, Division of Hematology Oncology, University of North Carolina at Chapel Hill, 27599, USA
    Clin Breast Cancer 9:S73-81. 2009
    ..Finally, the positive association between triple-negative breast cancer and BRCA mutations makes inhibition of poly(adenosine diphosphate-ribose) polymerase-1 an attractive therapeutic strategy that is in active study...
  49. ncbi request reprint Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer
    E Claire Dees
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Campus Box 7295, Chapel Hill, NC 27599 7295, USA
    Cancer Immunol Immunother 53:777-85. 2004
    ..DCs can be generated ex vivo from monocytes or CD34+ precursors. The ability to expand and safely administer CD34-derived DCs in patients with MBC that have received prior cytotoxic chemotherapy has not been evaluated...
  50. pmc Molecular characterization of basal-like and non-basal-like triple-negative breast cancer
    Aleix Prat
    Medical Oncology Department, Vall d Hebron Institute of Oncology, Barcelona, Spain
    Oncologist 18:123-33. 2013
    ....
  51. ncbi request reprint Gene expression profiling in breast cancer
    Shannon R Morris
    GlaxoSmithKline, Research Triangle Park and Division of Hematology Oncology, University of North Carolina, Chapel Hill, NC 27599 7305, USA
    Curr Opin Oncol 19:547-51. 2007
    ..The review is intended to highlight the most important advances in the field over recent years with an emphasis on those most relevant to the practicing oncologist...
  52. pmc Understanding and treating triple-negative breast cancer
    Carey Anders
    Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7305, USA
    Oncology (Williston Park) 22:1233-9; discussion 1239-40, 1243. 2008
    ....
  53. ncbi request reprint Guidelines for the initial management of metastatic brain tumors: role of surgery, radiosurgery, and radiation therapy
    Matthew G Ewend
    Division of Neurosurgery, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599, USA
    J Natl Compr Canc Netw 6:505-13; quiz 514. 2008
    ....
  54. doi request reprint Dysregulation of the epigenome in triple-negative breast cancers: basal-like and claudin-low breast cancers express aberrant DNA hypermethylation
    J Devon Roll
    Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 27599 USA UNC Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC 27599 USA Electronic address
    Exp Mol Pathol 95:276-87. 2013
    ..Identification of this distinguishing trait among triple-negative breast cancers forms the basis for development of new rational therapies that target the epigenome in patients with basal-like and claudin-low breast cancers. ..
  55. pmc Gene expression in extratumoral microenvironment predicts clinical outcome in breast cancer patients
    Erick Roman-Perez
    Department of Epidemiology, University of North Carolina at Chapel Hill, Campus Box 7435, Chapel Hill, NC 27599, USA
    Breast Cancer Res 14:R51. 2012
    ..We hypothesized that gene expression subtypes of breast cancer microenvironment can be defined and that these microenvironment subtypes have clinical relevance...
  56. doi request reprint Clinical trials in triple negative breast cancer
    Katherine E Reeder-Hayes
    Department of Hematology Oncology, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, USA
    Breast Dis 32:123-36. 2010
    ....
  57. pmc Tumor therapeutic response and vessel tortuosity: preliminary report in metastatic breast cancer
    Elizabeth Bullitt
    CASILab, CB 7062, University of North Carolina, Chapel Hill, NC 27599, USA
    Med Image Comput Comput Assist Interv 9:561-8. 2006
    ..In this preliminary study of 16 patients undergoing treatment for metastatic breast cancer we conclude that vessel shape may predict tumor response several months in advance of traditional methods...
  58. doi request reprint Quantifying the recruitment challenges with couple-based interventions for cancer: applications to early-stage breast cancer
    Steffany J Fredman
    University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    Psychooncology 18:667-73. 2009
    ....
  59. doi request reprint Reporting of race and ethnicity in breast cancer research: room for improvement
    Kelly W Mitchell
    Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA
    Breast Cancer Res Treat 118:511-7. 2009
    ..Low accrual of black subjects and failure to report accrual and outcomes by race in RCT may contribute to difficulty in understanding and overcoming health disparities in breast cancer...
  60. pmc The management of early-stage and metastatic triple-negative breast cancer: a review
    Carey K Anders
    Division of Hematology Oncology, Department of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 170 Manning Drive, Chapel Hill, NC 27599, USA
    Hematol Oncol Clin North Am 27:737-49, viii. 2013
    ..The general principles guiding the use of chemotherapy and radiation therapy do not differ dramatically between early-stage TNBC and non-TNBC. ..
  61. ncbi request reprint Gene-expression analysis and the basal-like breast cancer subtype
    Timothy J Finnegan
    The University of North Carolina, Division of Hematology Oncology, CB 7305, 3009 Old Clinic Building, Chapel Hill, NC 27599, USA
    Future Oncol 3:55-63. 2007
    ..This review discusses the molecular profiles of breast cancer with a focus on the clinical characteristics of, and treatment options for, the basal-like subtype...
  62. ncbi request reprint Radiation clastogenesis and cell cycle checkpoint function as functional markers of breast cancer risk
    William K Kaufmann
    Lineberger Comprehensive Cancer Center, Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Carcinogenesis 27:2519-27. 2006
    ..This study tested whether sporadic breast cancer was associated with constitutive radiation hypersensitivity...
  63. ncbi request reprint Adjuvant systemic therapy in young women
    Daniel R Carrizosa
    Division of Hematology Oncology, University of North Carolina at Chapel Hill, 27599 7305, USA
    Breast Dis 23:67-71. 2005
    ....
  64. ncbi request reprint Molecular profiling in breast cancer
    Shannon R Morris
    GlaxoSmithKline, Research Triangle Park, NC, USA
    Rev Endocr Metab Disord 8:185-98. 2007
    ..The increasingly sophisticated understanding allowed by this and similar technology promises future individualized therapy...
  65. ncbi request reprint Current treatment paradigms for the management of patients with brain metastases
    Matthew G Ewend
    Division of Neurological Surgery, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7060, USA
    Neurosurgery 57:S66-77; discusssion S1-4. 2005
    ..With advances in systemic therapy for cancer, the treatment of brain metastases is becoming an increasingly important determinant of the length of survival and quality of life for cancer patients...
  66. ncbi request reprint Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer
    Shannon R Morris
    GlaxoSmithKline, Research Triangle Park, North Carolina, USA
    Oncology (Williston Park) 20:1763-71; discussion 1771-2, 1774-6. 2006
    ..Overcoming that resistance to therapy is our next challenge. This review examines the current understanding of HER2 biology, the mechanisms of action of and resistance to trastuzumab, as well as new therapies on the horizon...
  67. ncbi request reprint Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer
    Nancy U Lin
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 26:1993-9. 2008
    ..We evaluated the safety and efficacy of lapatinib, an oral inhibitor of epidermal growth factor receptor (EGFR) and HER-2, in patients with HER-2-positive brain metastases...
  68. doi request reprint Research issues affecting preoperative systemic therapy for operable breast cancer
    Antonio C Wolff
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans St, Room 189, Baltimore, MD 21231 1000, USA
    J Clin Oncol 26:806-13. 2008
    ..PST requires an experienced and cohesive multidisciplinary team for it to fulfill its potential in both research and clinical care...
  69. pmc Polymorphisms in drug metabolism genes, smoking, and p53 mutations in breast cancer
    Beth O Van Emburgh
    Department of Cancer Biology, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, USA
    Mol Carcinog 47:88-99. 2008
    ....
  70. pmc Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer
    Erica L Mayer
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Breast Cancer Res 9:110. 2007
    ..Ongoing studies of novel agents may lead to improved therapeutic outcomes for this high-risk population...
  71. ncbi request reprint Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer
    Britta Weigelt
    Divisions of Experimental Therapy and Diagnostic Oncology, The Netherlands Cancer Institute, The Netherlands
    Cancer Res 65:9155-8. 2005
    ..Furthermore, our data imply that poor prognosis breast carcinomas classified either by the intrinsic gene set or the 70 prognosis genes represent distinct disease entities that seem sustained throughout the metastatic process...
  72. pmc Polymorphisms in CYP1B1, GSTM1, GSTT1 and GSTP1, and susceptibility to breast cancer
    Beth O Van Emburgh
    Department of Cancer Biology, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Oncol Rep 19:1311-21. 2008
    ..97; 95% CI=1.27-12.40). These results suggest the importance of estrogen/carcinogen metabolic enzymes in the etiology of breast cancer, especially in women before the age of 60, as well as preventative measures such as smoking cessation...
  73. ncbi request reprint Molecular classification and molecular forecasting of breast cancer: ready for clinical application?
    James D Brenton
    Cancer Genomics Program, Department of Oncology, University of Cambridge, Hutchison MRC Research Centre, Cambridge, United Kingdom CB22XZ
    J Clin Oncol 23:7350-60. 2005
    ....